Cardio-Metabolic

Therapy area with increasing patients globally due to rising risk factors necessitating innovative interventions for metabolic diseases

Focus for Innovation : Cardiovascular disease area is well served with multiple pharmacotherapy globally with increasing innovation in medical device space. Pharma landscape is shifting towards diseases with cardiovascular risk factors with major focus of innovation in diabetes, lipid disorders and obesity.

Broader Market Relevance : Cardiovascular risk factors are increasing even in emerging markets due to significant change in the life-style and eating habits. Obesity has been a focal point for recent innovative therapies, but it is highly unlikely that these therapies will reach to broader population quickly due to cost and patent protection. Diabetes is becoming very prevalent but novel therapies and convenient alternatives take lots of time to serve global population

Alternatives : Current effective therapies (eg. GLP-1 agonists) for obesity and diabetes are peptides administered parenterally which limits broader access due to cost as well as manufacturing and supply chain constraints globally. So, there is an opportunity to develop cost-effective small molecule oral alternatives for proven targets in parallel to innovation in developed countries. There is also a need to tailor the solutions serving the need of emerging markets as patients characteristics, clinical presentations, and therapy needs are different.